Pharmacological Treatments of Negative Symptoms in Schizophrenia-An Update.

negative symptoms pharmacological treatment schizophrenia

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
23 Sep 2024
Historique:
received: 09 09 2024
accepted: 21 09 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

Schizophrenia is a chronic psychotic disorder comprising positive symptoms, negative symptoms, and cognitive deficits. Negative symptoms are associated with stigma, worse functional outcomes, and a significant deterioration in quality of life. Clinical diagnosis is challenging despite its significance, and current treatments offer little improvement in the burden of negative symptoms. This article reviews current pharmacological strategies for treating negative symptoms. Dopaminergic, glutamatergic, serotonergic, noradrenergic, cholinergic, anti-inflammatory compounds, hormones, and psychostimulants are explored. Finally, we review pharmacological global treatment guidelines for negative symptoms. In general, switching to a second-generation antipsychotic seems to be most often recommended for patients with schizophrenia on first-generation antipsychotics, and an add-on antidepressant is considered when depression is also present. However, the treatment of negative symptoms remains an unmet need. Future, larger clinical studies and meta-analyses are needed to establish effective pharmacological agents for the effective treatment of negative symptoms.

Identifiants

pubmed: 39337126
pii: jcm13185637
doi: 10.3390/jcm13185637
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Evangelia Maria Tsapakis (EM)

3rd Department of Psychiatry, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Department of Neurosciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Michael Treiber (M)

3rd Department of Psychiatry, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.
Comprehensive Center for Clinical Neurosciences and Mental Health (C3NMH), Medical University of Vienna, 1090 Vienna, Austria.

Calypso Mitkani (C)

3rd Department of Psychiatry, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Department of Neurology, Agios Pavlos General Hospital of Thessaloniki, 55134 Thessaloniki, Greece.

Zoe Drakaki (Z)

Department of Neurosciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Anastasios Cholevas (A)

Department of Neurosciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Cleanthe Spanaki (C)

Department of Neurosciences, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Department of Neurology, University Hospital of Heraklion, Voutes, 71110 Crete, Greece.

Konstantinos N Fountoulakis (KN)

3rd Department of Psychiatry, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.

Classifications MeSH